| Identification | Back Directory | [Name]
ABBV-744 | [CAS]
2138861-99-9 | [Synonyms]
CPD1639
CS-2875
ABBV-744
ABBV-744; ABBV 744; ABBV744;2138861-99-9
N-Ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(1-hydroxy-1-methylethyl)phenyl]-6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide
1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(1-hydroxy-1-methylethyl)phenyl]-6,7-dihydro-6-methyl-7-oxo- | [Molecular Formula]
C28H30FN3O4 | [MDL Number]
MFCD31657409 | [MOL File]
2138861-99-9.mol | [Molecular Weight]
491.55 |
| Chemical Properties | Back Directory | [Boiling point ]
663.7±55.0 °C(Predicted) | [density ]
1.262±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:33.57(Max Conc. mg/mL);68.29(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:3):0.25(Max Conc. mg/mL);0.51(Max Conc. mM)
DMF:30.0(Max Conc. mg/mL);61.03(Max Conc. mM) | [form ]
A crystalline solid | [pka]
13.77±0.40(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
ABBV 744 is a bromodomain and extra-??terminal (BET) inhibitor used as a combination therapy for cancer treatment. | [Biological Activity]
ABBV-744 is a BDII-selective BET bromodomain inhibitor that inhibits BRD2, BRD3 and BRD4. It can be further studied for the treatment of acute myeloid leukemia and cancer. | [in vitro]
ABBV-744 is a potent BDII inhibitor that inhibits BRD2/3/4. The binding preference for BDII is more than 250 times that for BDI, with favorable drug-like properties. It is also an inhibitor of the androgen receptor transduction pathway. | [in vivo]
The maximum tolerated dose of ABBV-744 induces tumor growth inhibition in AML and prostate cancer xenograft models. | [target]
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
|
|
Tags:2138861-99-9
Related Product Information
|
|
2080306-23-4
869296-13-9
1196509-60-0
1665195-94-7
1985607-83-7
610318-03-1
1467093-03-3
|
|